When to recommend allogeneic transplant in multiple myeloma

Morie A. Gertz

doi:10.3109/10428194.2015.1052808

When to recommend allogeneic transplant in multiple myeloma

Morie A. Gertz

Hematology

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

Original language	English (US)
Pages (from-to)	2512-2517
Number of pages	6
Journal	Leukemia and Lymphoma
Volume	56
Issue number	9
DOIs	https://doi.org/10.3109/10428194.2015.1052808
State	Published - Sep 2 2015

Keywords

Allogeneic transplant
matched donors
matched-unrelated donors
multiple myeloma
reduced-intensity conditioning
transplant

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2015.1052808

Cite this

@article{b84deb18f278416391ee023c1e9a1317,

title = "When to recommend allogeneic transplant in multiple myeloma",

abstract = "Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.",

keywords = "Allogeneic transplant, matched donors, matched-unrelated donors, multiple myeloma, reduced-intensity conditioning, transplant",

author = "Gertz, {Morie A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Informa UK, Ltd.",

year = "2015",

month = sep,

day = "2",

doi = "10.3109/10428194.2015.1052808",

language = "English (US)",

volume = "56",

pages = "2512--2517",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - When to recommend allogeneic transplant in multiple myeloma

AU - Gertz, Morie A.

PY - 2015/9/2

Y1 - 2015/9/2

N2 - Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

AB - Utilization of allogeneic transplant in the management of multiple myeloma has been actively pursued for nearly 30 years. In this paper, the existing data for use of transplant is reviewed as primary therapy, as salvage and for genetic high-risk disease. The relative merits of using a matched-unrelated donor vs. an HLA-matched donor and what impact the introduction of the novel agents has on the decision to transplant will be covered.

KW - Allogeneic transplant

KW - matched donors

KW - matched-unrelated donors

KW - multiple myeloma

KW - reduced-intensity conditioning

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=84946049303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946049303&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1052808

DO - 10.3109/10428194.2015.1052808

M3 - Review article

C2 - 25989864

AN - SCOPUS:84946049303

SN - 1042-8194

VL - 56

SP - 2512

EP - 2517

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

When to recommend allogeneic transplant in multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this